These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

258 related items for PubMed ID: 8996140

  • 1. Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study.
    O'Reilly S, Fleming GF, Barker SD, Walczak JR, Bookman MA, McGuire WP, Schilder RJ, Alvarez RD, Armstrong DK, Horowitz IR, Ozols RF, Rowinsky EK.
    J Clin Oncol; 1997 Jan; 15(1):177-86. PubMed ID: 8996140
    [Abstract] [Full Text] [Related]

  • 2. Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors.
    Rowinsky EK, Grochow LB, Sartorius SE, Bowling MK, Kaufmann SH, Peereboom D, Donehower RC.
    J Clin Oncol; 1996 Apr; 14(4):1224-35. PubMed ID: 8648378
    [Abstract] [Full Text] [Related]

  • 3. Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer.
    Herben VM, Panday VR, Richel DJ, Schellens JH, van der Vange N, Rosing H, Beusenberg FD, Hearn S, Doyle E, Beijnen JH, ten Bokkel Huinink WW.
    J Clin Oncol; 1999 Mar; 17(3):747-55. PubMed ID: 10071262
    [Abstract] [Full Text] [Related]

  • 4. Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence.
    Rowinsky EK, Kaufmann SH, Baker SD, Grochow LB, Chen TL, Peereboom D, Bowling MK, Sartorius SE, Ettinger DS, Forastiere AA, Donehower RC.
    J Clin Oncol; 1996 Dec; 14(12):3074-84. PubMed ID: 8955652
    [Abstract] [Full Text] [Related]

  • 5. Cisplatin-topotecan-paclitaxel weekly administration with G-CSF support for ovarian and small-cell lung cancer patients: a dose-finding study.
    Frasci G, Panza N, Comella P, Cartení G, Guida T, Nicolella GP, Natale M, Lombardi R, Apicella A, Pacilio C, Gravina A, Lapenta L, Comella G.
    Ann Oncol; 1999 Mar; 10(3):355-8. PubMed ID: 10355583
    [Abstract] [Full Text] [Related]

  • 6. High-dose topotecan with granulocyte-colony stimulating factor in fluoropyrimidine-refractory colorectal cancer: a phase II and pharmacodynamic study.
    Rowinsky EK, Baker SD, Burks K, O'Reilly S, Donehower RC, Grochow LB.
    Ann Oncol; 1998 Feb; 9(2):173-80. PubMed ID: 9553662
    [Abstract] [Full Text] [Related]

  • 7. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.
    Miller AA, Hargis JB, Lilenbaum RC, Fields SZ, Rosner GL, Schilsky RL.
    J Clin Oncol; 1994 Dec; 12(12):2743-50. PubMed ID: 7527456
    [Abstract] [Full Text] [Related]

  • 8. Phase I trial of intravenous cisplatin-topotecan chemotherapy for three consecutive days in patients with advanced solid tumors: parallel topotecan escalation in two fixed platinum dosing schemes.
    Pentheroudakis G, Briasoulis E, Karavassilis V, Mauri D, Tzamakou E, Rammou D, Pavlidis N.
    Chemotherapy; 2005 May; 51(2-3):154-61. PubMed ID: 15886476
    [Abstract] [Full Text] [Related]

  • 9. Phase I study of paclitaxel and topotecan in patients with advanced tumors: a cancer and leukemia group B study.
    Lilenbaum RC, Ratain MJ, Miller AA, Hargis JB, Hollis DR, Rosner GL, O'Brien SM, Brewster L, Green MR, Schilsky RL.
    J Clin Oncol; 1995 Sep; 13(9):2230-7. PubMed ID: 7545219
    [Abstract] [Full Text] [Related]

  • 10. A phase I study of paclitaxel, topotecan, cisplatin and Filgrastim in patients with newly diagnosed advanced ovarian epithelial malignancies: a Gynecologic Oncology Group study.
    Armstrong DK, Bookman MA, McGuire W, Bristow RE, Schilder JM, Gynecologic Oncology Group.
    Gynecol Oncol; 2007 Jun; 105(3):667-71. PubMed ID: 17368526
    [Abstract] [Full Text] [Related]

  • 11. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study.
    Creemers GJ, Bolis G, Gore M, Scarfone G, Lacave AJ, Guastalla JP, Despax R, Favalli G, Kreinberg R, Van Belle S, Hudson I, Verweij J, Ten Bokkel Huinink WW.
    J Clin Oncol; 1996 Dec; 14(12):3056-61. PubMed ID: 8955650
    [Abstract] [Full Text] [Related]

  • 12. Phase I dose escalation study of gemcitabine and paclitaxel plus colony-stimulating factors in previously treated patients with advanced breast and ovarian cancer.
    Iaffaioli RV, Tortoriello A, Santangelo M, Turitto G, Libutti M, Benassai G, Frattolillo A, Ciccarelli PD, De Rosa P, Crovella F, Carbone I, Barbarisi A.
    Clin Oncol (R Coll Radiol); 2000 Dec; 12(4):251-5. PubMed ID: 11005695
    [Abstract] [Full Text] [Related]

  • 13. Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer: a phase I trial.
    Meerpohl HG, du Bois A, Luck HJ, Kühnle H, Möbus V, Kreienberg R, Bauknecht T, Köchli O, Bochtler H, Diergarten K.
    Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-17-S2-22. PubMed ID: 9045330
    [Abstract] [Full Text] [Related]

  • 14. Phase I study of alternating doublets of topotecan/carboplatin and paclitaxel/carboplatin in patients with newly diagnosed, advanced ovarian cancer.
    Gordon AN, Hancock KC, Matthews CM, Messing M, Stringer CA, Doherty MG, Teneriello M.
    Gynecol Oncol; 2002 Apr; 85(1):129-35. PubMed ID: 11925132
    [Abstract] [Full Text] [Related]

  • 15. Phase I study of docetaxel and topotecan in patients with solid tumors.
    Tkaczuk KH, Zamboni WC, Tait NS, Meisenberg BR, Doyle LA, Edelman MJ, Hausner PF, Egorin MJ, Van Echo DA.
    Cancer Chemother Pharmacol; 2000 Apr; 46(6):442-8. PubMed ID: 11138457
    [Abstract] [Full Text] [Related]

  • 16. Phase I trial of paclitaxel, carboplatin, and topotecan with or without filgrastim (granulocyte-colony stimulating factor) in the treatment of patients with advanced, refractory cancer.
    Hainsworth JD, Burris HA, Morrissey LH, Greco FA.
    Cancer; 1999 Mar 01; 85(5):1179-85. PubMed ID: 10091804
    [Abstract] [Full Text] [Related]

  • 17. Phase I trial of escalating doses of paclitaxel combined with fixed doses of cisplatin and doxorubicin in advanced endometrial cancer and other gynecologic malignancies: a Gynecologic Oncology Group study.
    Fleming GF, Fowler JM, Waggoner SE, Copeland LJ, Greer BE, Horowitz I, Sutton G, Schilder RJ, Fracasso PM, Ball HG, McGuire WP.
    J Clin Oncol; 2001 Feb 15; 19(4):1021-9. PubMed ID: 11181665
    [Abstract] [Full Text] [Related]

  • 18. Phase I and pharmacologic study of sequences of paclitaxel and cyclophosphamide supported by granulocyte colony-stimulating factor in women with previously treated metastatic breast cancer.
    Kennedy MJ, Zahurak ML, Donehower RC, Noe DA, Sartorius S, Chen TL, Bowling K, Rowinsky EK.
    J Clin Oncol; 1996 Mar 15; 14(3):783-91. PubMed ID: 8622024
    [Abstract] [Full Text] [Related]

  • 19. Phase II feasibility study of sequential couplets of Cisplatin/Topotecan followed by paclitaxel/cisplatin as primary treatment for advanced epithelial ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group Study.
    Hoskins P, Eisenhauer E, Vergote I, Dubuc-Lissoir J, Fisher B, Grimshaw R, Oza A, Plante M, Stuart G, Vermorken J.
    J Clin Oncol; 2000 Dec 15; 18(24):4038-44. PubMed ID: 11118464
    [Abstract] [Full Text] [Related]

  • 20. Prophylactic granulocyte colony-stimulating factor allows escalation of chemotherapeutic dose intensity in advanced epithelial ovarian cancer.
    Fanning J, Hilgers RD.
    Gynecol Oncol; 1996 Dec 15; 63(3):323-7. PubMed ID: 8946866
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.